ம்ட் வடமேற்கு பல்கலைக்கழகம் ஃபைன்பெர்க் பள்ளி ஆஃப் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

February 01, 2021 Use of low-dose rivaroxaban (Xarelto; Bayer/Janssen) plus aspirin improves outcomes in patients with chronic atherosclerotic vascular disease irrespective of body size, a secondary analysis of the COMPASS trial shows. In that trial, combining rivaroxaban 2.5 mg twice daily and aspirin 100 mg per day reduced the composite of CV death, stroke, or MI at the cost of more major bleeding, and those effects did not vary significantly across categories of body weight or body mass index (BMI), researchers led by Tomasz Guzik, MD, PhD (University of Glasgow, Scotland), report. The results, published in the February 9, 2021, issue of the Journal of the American College of Cardiology, “show that this combination of a vascular dose of rivaroxaban with aspirin can be safely used across a broad range of body weights and does not necessitate dose adjustments,” Guzik told TCTMD.

United statesUnited kingdomTomasz guzikKarlyn martinSadiya khanBayer janssenPhd university of glasgowMd northwestern university feinberg school of medicineAmerican heart associationHeart rhythm societyJournal of the american college cardiologyAmerican college of cardiologyInternational society on thrombosisAmerican collegeInternational societyNorthwestern university feinberg school